Marshall Urist, who serves as Executive Vice President, Research & Investments at Royalty Pharma PLC (NASDAQ:RPRX), sold 20,000 Class A Ordinary Shares on January 30, 2026. The transaction generated approximately $821,810 in proceeds, with sale prices recorded between $40.88 and $41.28 per share.
Following that disposition, Urist's holdings consist of 19,020 Class A Ordinary Shares held indirectly through an IRA and 7,398 shares held directly.
The disposition was carried out under a pre-arranged 10b5-1 trading plan the executive adopted on September 16, 2025.
Separately, Royalty Pharma disclosed a suite of corporate developments and full-year performance metrics for 2025. The company said it reached $10 billion in the royalty funding market during 2025, a figure the company characterizes as a record and one that represents a 40% increase over the previous five-year average.
In its deal activity, Royalty Pharma reported $4.7 billion in announced transactions for the year, which the company stated corresponds to a 40% market share for those announced deals, and it deployed $2.6 billion in capital over the same period.
On the shareholder return front, Royalty Pharma increased its quarterly dividend by 6.8% to $0.235 per Class A ordinary share for the first quarter of 2026. The company set a payment date of March 10, 2026, with a record date for shareholders of February 20, 2026.
In a material transaction tied to its royalty portfolio, Royalty Pharma agreed to acquire the final portion of PTC Therapeutics’ remaining royalty on Roche’s spinal muscular atrophy treatment Evrysdi. The deal involves $240 million in upfront consideration, with potential additional milestone payments of up to $60 million. As a result of the acquisition, Royalty Pharma now holds 100% of the tiered royalty structure on Evrysdi, which ranges from 8% to 16% of worldwide net sales.
Following these moves, UBS revised its investment view on Royalty Pharma, upgrading the stock from Neutral to Buy and raising its price target to $49.00. UBS cited what it described as an attractive growth profile after the series of royalty transactions.
The facts above are as reported by Royalty Pharma and disclosed filings referenced by the company; no additional forward-looking details or projections were provided in the material presented here.